as of 11-18-2026 10:43am EST
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.
| Founded: | 1979 | Country: | France |
| Employees: | N/A | City: | 69120 VAULX EN VELIN |
| Market Cap: | 206.3M | IPO Year: | 1998 |
| Target Price: | $8.30 | AVG Volume (30 days): | 60.6K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.71 | EPS Growth: | -41.82 |
| 52 Week Low/High: | $2.80 - $6.40 | Next Earning Date: | 11-05-2026 |
| Revenue: | $70,527,000 | Revenue Growth: | 1.63% |
| Revenue Growth (this year): | -27.62% | Revenue Growth (next year): | 33.55% |
| P/E Ratio: | -4.00 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
SEC 8-K filings with transcript text
Nov 5, 2026
2 exh_991.htm
Exhibit 99.1
FocalTherics™ Reports Third Quarter 2026 Financial Results
45% Revenue Increase and 44% Growth in U.S. Procedure Volume Year-to-date
AUSTIN, Texas, November 5, 2026 - FocalTherics™ (Nasdaq: FOCL) (the “Company”[1]), a global leader in robotic focal therapy, today announced financial results for the third quarter of 2026.
Third Quarter 2026 Results and Recent Highlights
·Increased Revenue to $9.8 million, a 26% Increase Compared to the Prior Year Period
·32% Increase in U.S. Procedure Volume over the Prior Year Period
·Recorded Seven Focal One® Capital System Sales compared to Six in the Prior Year Period,
·Expanded Focal One System Installed Base to 192, including 98 in the U.S. and 94 Internationally
·Increased Gross Margin to 51.4%, Compared to 46.6% in the Prior Year Period
·Expanded Commercial Focal One Endometriosis Programs to Three Centers in Europe
·Positive Coverage Policies Published by Major Commercial Payers for HIFU in Radiorecurrent Prostate Cancer
“We demonstrated steady commercial momentum in the third quarter, highlighted by expanding adoption across multiple new regions and additional system sales in the United States, Turkey, Mexico, and France,” said Ryan Rhodes, CEO of FocalTherics. “U.S. procedure volumes accelerated year-over-year to 32% for the third quarter of 2026, compared to 15% in 2025. Driven by our sustained commercial traction, accelerating technology adoption, and our focus on our HIFU opportunity, we remain highly confident in our growth strategy and on the opportunity ahead as we close out the year.”
Third Quarter 2026 Financial Results
Total revenue for the third quarter of 2026 was $9.8 million, compared to $7.8 million for the same period in 2025, representing an increase of 26% year-over-year. The Company sold seven Focal One systems during the quarter, versus six systems in the same period in 2025, representing a year-over-year growth of 17%. The Company’s U.S. Focal One procedures grew 32% year-over-year.
Gross margin for the third quarter of 2026 was 51.4%, compared to 46.6% in the prior year period. The increase in gross margin was primarily attributable to improvement on standard cost of the Focal One and higher average selling price of our Focal One systems and Focalpaks.
Operating expenses were $12.8 million for the third quarter of 2026, compared to $10.3 million in the prior year period. The increase was due to incremental headcount-related compensation costs including higher stock-based compensation, and additional sales and marketing expenses related to various Urology meetings and events.
Operating loss was $7.8 million for the third quarter of 2026, compared to $6.7 million in the prior year period. Net loss was $4.5 million for the third quarter of 2026, or ($0.10) per share, compared to a net loss of $5.9 million, or ($0.16) per share in the prior year period. The decrease in net loss was primarily attributable to favorable non-cash impact of $2.6 million related to change in fair value of the European Investment Bank warrants and $0.5 million foreign currency exchange gain, partially offset by the higher operating loss of $1.1 million and $0.4 million of interest expense on the Tranche A and Tranche B drawdown.
Cash and cash equivalents as of September 30, 2026 totaled $56.3 million.
Narrowing 2026 Guidance
We are narrowing our full-year 2026 revenue guidance to be in the range
of $50.0 to $52.0 million, representing 34% to 39% growth over 2025, from the prior range of $50.0 to $54.0 million.
We have included standalone historical financials for the HIFU business at the end of the document
Conference Call Information
A conference call and webcast to discuss the second quarter 2026 financial results will be hosted by Ryan Rhodes, Chief Executive Officer and Ken Mobeck, Chief Financial Officer. Please refer to the information below for conference call dial-in information and webcast registration.
Date: Thursday, November 5, 2026, at 4:30 p.m. Eastern Time
Domestic: 1-833-419-0865
International: 1-785-838-9333
Passcode:
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1776674&tp_key=37ee4700b1
About FocalTherics
A recognized global leader in robotic focal therapy, FocalTherics develops, manufactures, and markets minimally invasive medical devices worldwide to treat various conditions using proprietary focused ultrasound technology. The Company’s flagship platform, Focal One Robotic HIFU, combines advanced imaging, real-time treatment planning, robotic precision, and HIFU technology to deliver personalized focal therapy designed to optimize clinical outcomes while preserving quality of life.
In addition to historical information, this press release contains forward-looking statements within the meaning of applicable federal securities laws, including Section 27A of the U.S. Securities Act of 1933 (the “Securities Act”) or Section 21E of the
Aug 13, 2026
Aug 11, 2026
See how FOCL stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "FOCL EDAP TMS S.A. American Depositary Shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.